Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer
Non-small cell lung cancer(NSCLC)is a prevalent tumour type in our country,with lung squamous car-cinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma.Epidermal growth factor receptor(EGFR)is a significant driver gene in lung cancer,and EGFR mutation frequency is considerably lower in lung squamous carcinoma in comparison to lung adenocarcinoma.Although targeted therapy against EGFR has demonstrated significant advancements in lung adenocarcinoma,while progress in lung squamous carcinoma has been relatively sluggish.This paper reviews recent stud-ies on molecular targeted therapy for EGFR-mutated lung squamous carcinoma and summarises the efficacy of EGFR-tyrosine kinase inhibitors(TKIs)in treating squamous carcinoma of the lung,in order to provide a reference for treating patients with EGFR-mutated squamous carcinoma of the lung.
国家科技期刊平台
NSTL
万方数据
维普
